Donate For Public and Patients Store Search

C014 - Infectious Diseases

Saturday, March 2; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify a variety of infectious diseases, both common and uncommon
  • Design a treatment plan for selected cutaneous infections
  • Utilize, wherever feasible, preventative vaccines for select infections

Description

This course will review both essential and new, contemporary information regarding selected bacterial, fungal, biral and parasitic cutaneous infections. Histologic means of diagnosis will be reviewed. Use of vaccines will be highlighted.

Disclosures

  • Elewski, Boni E., MD: AbbVie – I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding); Celgene Corporation – C(H), I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – A(H); Incyte Corporation – I(Grants/Research Funding); InflaRx GmbH – I(Grants/Research Funding); Janssen-Ortho Inc. – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – A(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H); Menlo Therapeutics – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Novan – C(H); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H), I(Grants/Research Funding); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – A(H);
  • High, Whitney A., MD, JD: no financial relationships exist with commercial interests.
  • Mesinkovska, Natasha Atanaskova, MD, PhD: BiologicsMD, Inc. – C(H);
  • Rapini, Ronald P., MD: Elsevier Inc. – O(IP);
  • Rosen, Theodore, MD: Foamix – A(H); Medimetriks Pharmaceuticals, Inc. – C(H); Menlo Therapeutics – A(H); Valeant Pharmaceuticals International – C(H);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
  • Tyring, Stephen K., MD, PhD: Agenus Inc. – I(Grants/Research Funding); AiCuris GmbH & Co. KG – I(Grants/Research Funding); Genocea Biosciences – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Nycomed Amersham – I(Grants/Research Funding); Vical Incorporated – I(Grants/Research Funding);
Schedule
Saturday, March 2
9:00 AM
Dr. High / Histologic Pearls
9:30 AM
Dr. Tyring / Clinical Aspects of Herpesvirus Infection
10:00 AM
Dr. Mesinkovska / Cutaneous Infections in Returning Travelers
10:20 AM
Dr. Elewski / American Endemic Fungi
10:40 AM
Dr. Rapini / Bites, Stings and Creepy Things
11:00 AM
Dr. Tomecki / Vaccines: Present and Future
11:30 AM
Dr. Rosen / Resurgent STDs
Event Details
  • Date
    Saturday, March 2
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 154A
  • CME Credits
    3.00
  • Type
    Ticketed
Directors/Co-Directors
  • Theodore Rosen, MD, FAAD
Speakers
  • Boni E. Elewski, MD, FAAD - Handout
  • Kenneth J. Tomecki, MD, FAAD
  • Natasha Atanaskova Mesinkovska, MD, PhD, FAAD
  • Ronald P. Rapini, MD, FAAD - Handout
  • Stephen K. Tyring, MD, PhD, FAAD
  • Whitney A. High, MD, JD, FAAD